CSIMarket
 
Assembly Biosciences Inc   (ASMB)
Other Ticker:  
 
 
Price: $11.8000 $-0.37 -3.040%
Day's High: $12.1 Week Perf: -7.67 %
Day's Low: $ 11.60 30 Day Perf: 0.85 %
Volume (M): 10 52 Wk High: $ 20.04
Volume (M$): $ 116 52 Wk Avg: $11.36
Open: $12.05 52 Wk Low: $7.69



 Market Capitalization (Millions $) 52
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Assembly Biosciences Inc
Assembly Biosciences Inc is a biotechnology company that focuses on developing innovative therapeutics for various diseases. The company primarily works in the field of microbiome, which refers to the collection of microorganisms residing in the human body.

Assembly Biosciences aims to develop therapies that can address serious health conditions by selectively targeting the microbiome. They believe that by modifying the microbiome, it is possible to bring about positive changes in human health.

The company's therapeutic pipeline includes potential treatments for hepatitis B virus (HBV), C. difficile infection, and other gastrointestinal conditions. Assembly Biosciences is known for its expertise in molecular biology, biochemistry, and microbiology, which enables them to develop novel drug candidates.

In addition to developing their own products, Assembly Biosciences also collaborates with other pharmaceutical companies to advance research and development in the microbiome space. They work on identifying new drug targets, conducting clinical trials, and ultimately bringing innovative therapies to patients in need.

Overall, Assembly Biosciences Inc is a biotech company that focuses on harnessing the power of the microbiome to develop effective treatments for various diseases, particularly in the field of gastroenterology.


   Company Address: 331 Oyster Point Blvd. South San Francisco 94080 CA
   Company Phone Number: 509-4583   Stock Exchange / Ticker: NASDAQ ASMB
   ASMB is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Assembly Bio Common Stock Set to Begin Trading on Split-Adjusted Basis, Impacts Shareholders

Published Thu, Feb 8 2024 1:01 PM UTC



Assembly Bio common stock is expected to commence trading on a split-adjusted basis on February 12, 2024, paving the way for potential changes in the market dynamic and its impact on existing shareholders. This announcement follows previous news on , which had a noticeable impact on the company's performance.
As of the writing of this article, Assembly Bioscie...

Product Service News

Accelerating the Antiviral Revolution: Assembly Biosciences Sets Transcendent Path for 2024 Clinical Pipeline Development

Published Thu, Jan 4 2024 1:01 PM UTC

Assembly Biosciences Outlines Anticipated Development Milestones for 2024; Strong Progress Expected for Clinical PipelineAssembly Biosciences, a renowned biotechnology company specializing in the development of innovative antiviral therapeutics targeting serious viral diseases, has unveiled its anticipated milestones and progress for its clinical pipeline during the year 202...

Assembly Biosciences Inc

Assembly Biosciences Inc revolutionizes fiscal third quarter, embarking on -$23.401 million operating shortfall

Financial News Report: Assembly Biosciences Inc Reports Operating Shortfall in Q3 2023
The Major Pharmaceutical Preparations sector is closely monitoring the third-quarter results of Assembly Biosciences Inc, a company that specializes in biopharmaceutical development. The latest report reveals an operating shortfall of $-15.048 million for the July to September 2023 reporting season. It is worth noting that the company has not disclosed any top-line figures at this point.
Comparatively, this operating shortfall is an improvement from the third quarter of 2022, where the company reported a larger operating shortfall of $-23.401 million. This key indicator sheds light on the financial trajectory of Assembly Biosciences Inc, signaling a positive trend towards cost-effectiveness and meeting its targets.

Assembly Biosciences Inc

Assembly Biosciences Inc Announces Unexpected Operating Shortfall Improvement in Q2 2023


Introduction
Assembly Biosciences Inc, a major participant in the pharmaceutical preparations market, has recently reported unexpected adjustments during the April to June reporting cycle. These changes have caught investors by surprise, as they were not anticipated. However, there is an optimistic silver lining among these adjustments, with an operating shortfall decrease that offers confidence in the company's future performance. This article explores the recent developments at Assembly Biosciences Inc and analyzes its market and stock performance.
Operating Shortfall Improvements Drive Optimism
During the reporting period from April to June 2023, Assembly Biosciences Inc experienced a favorable improvement in its operating shortfall. The operating shortfall reduced to $-17.488 million, highlighting a notable positive surprise exempt from the usual standards. Moreover, this represents a significant progression from the $-24.573 million operating shortfall reported in the same period the previous year.

Assembly Biosciences Inc

Assembly Biosciences Inc Reports Operating Deficit in Q1 2023, Raises Concerns Amidst Lack of Revenue

Investors in the stock market must take a cautious approach when considering investing in the Major Pharmaceutical Preparations sector. Recent analysis by sector researchers reveals that the Assembly Biosciences Inc has reported an operating deficit of $-19.559 million for the period from January to March 31, 2023. This is a cause for concern, especially since the company has not reported any revenue yet.
On a positive note, the company's operating instance has outperformed the same category in the corresponding period a year before. While Assembly Biosciences Inc primarily operates in the research stage, this positive development is worth noting. It is also heartening to learn that the company's deficit has receded to $-18.950 million from $-23.091 million in the first quarter of 2022, which could aid the business in becoming a doyen in the industry.
However, investors must not jump to conclusions based on this information alone. It is important to consider other factors such as the economic climate, industry trends, and the performance of other companies in the sector before making any investment decisions.
Furthermore, Assembly Biosciences Inc is expected to report its next financial results on May 11, 2023. It is wise to wait for this report before investing in the company. The company's financial performance will give a clearer picture of its health and prospects, and investors can make an informed decision based on that information.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com